Font, A, Mellado, B, Climent, MA, Virizuela, JA, Oudard, S, Puente, J, Castellano, D, González-del-Alba, A, Pinto, A, Morales-Barrera, R, Rodriguez-Vida, A, Fernandez, PL, Teixido, C, Jares, P, Aldecoa, I, Gibson, N, Solca, F, Mondal, S, Lorence, RM, Serra, J, Real, FX (2023).
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
BRITISH JOURNAL OF CANCER. Article. 130(3):434-441.
[doi:10.1038/s41416-023-02513-6]
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP (2023).
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. Article. 115(12):1605-1615.
[doi:10.1093/jnci/djad155]
Rodríguez-Izquierdo, M, Del Cañizo, CG, Rubio, C, Reina, IA, Arroyo, MH, Antolin, AR, Porto, MD, Guerrero-Ramos, F (2023).
Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in Non-Muscle-Invasive Bladder Cancer
Cancers. Review. 15(23).
[doi:10.3390/cancers15235554]
Oh, D, Maqueda, MA, Quinn, DI, O'Dwyer, PJ, Chau, I, Kim, SY, Duran, I, Castellano, D, Berlin, J, Mellado, B, Williamson, SK, Lee, KW, Marti, F, Mathew, P, Saif, MW, Wang, D, Chong, E, Hilger-Rolfe, J, Dean, JP, Arkenau, HT (2023).
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
BMC CANCER. Article. 23(1).
[doi:10.1186/s12885-023-11539-1]
Rosenberg, JE, Powles, T, Sonpavde, GP, Loriot, Y, Duran, I, Lee, JL, Matsubara, N, Vulsteke, C, Castellano, D, Mamtani, R, Wu, C, Matsangou, M, Campbell, M, Petrylak, DP (2023).
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
ANNALS OF ONCOLOGY. Article. 34(11):1047-1054.
[doi:10.1016/j.annonc.2023.08.016]
Grimm, MO, Esteban, E, Barthelemy, P, Schmidinger, M, Busch, J, Valderrama, BP, Charnley, N, Schmitz, M, Schumacher, U, Leucht, K, Foller, S, Baretton, G, Duran, I, de Velasco, G, Priou, F, Maroto, P, Albiges, L (2023).
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
LANCET ONCOLOGY. Article. 24(11):1252-1265.
[doi:10.1016/S1470-2045(23)00449-7]
Drakaki, A, Powles, T, Bamias, A, Martin-Liberal, J, Shin, SJ, Friedlander, T, Tosi, D, Park, C, Gomez-Roca, C, Lobbedez, FJ, Castellano, D, Morales-Barrera, R, Moreno-Candilejo, I, Flechon, A, Yuen, K, Rishipathak, D, Dupree, K, Young, F, Michielin, F, Shemesh, CS, Steinberg, EE, Williams, P, Lee, JL (2023).
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
CLINICAL CANCER RESEARCH. Article. 29(21):4373-4384.
[doi:10.1158/1078-0432.CCR-23-0798]
Gomez, EG, Castineira, RC, Burgos, J, Antolin, AR, Miles, BJ, Salamanca, JIM, Bianco, F, Fernandez, L, Calmarza, I, Pastor, J, Butler, RG, de Pedro, N (2023).
ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer
Prostate. Article. 83(14):1323-1331.
[doi:10.1002/pros.24594]
Kristeleit, R, Leary, A, Delord, JP, Moreno, V, Oaknin, A, Castellano, D, Shappiro, GI, Fernández, C, Kahatt, C, Alfaro, V, Siguero, M, Rueda, D, Zeaiter, A, Awada, A, Santaballa, A, Zaman, K, Sehouli, J, Subbiah, V (2023).
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
INVESTIGATIONAL NEW DRUGS. Article. 41(5):677-687.
[doi:10.1007/s10637-023-01383-2]
Bakaloudi, DR, Talukder, R, Lin, GI, Makrakis, D, Diamantopoulos, LN, Tripathi, N, Agarwal, N, Zakopoulou, R, Bamias, A, Brown, JR, Pinato, DJ, Korolewicz, J, Jindal, T, Koshkin, VS, Murgic, J, Miletic, M, Frobe, A, Johnson, J, Zakharia, Y, Drakaki, A, Rodriguez-Vida, A, Rey-Cárdenas, M, Castellano, D, Buznego, LA, Duran, I, Carballeira, CC, Barrera, RM, Marmorejo, D, McKay, RR, Stewart, T, Gupta, S, Ruplin, AT, Yu, EY, Khaki, AR, Grivas, P (2023).
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience
CLINICAL GENITOURINARY CANCER. Article. 21(5):584-593.
[doi:10.1016/j.clgc.2023.06.008]
Alvarez, SJ, Utrera, NRM, Ojeda, JMD, Sutil, RS, Gil-Moradillo, J, Guerrero-Ramos, F, Hernández-Arroyo, M, de la Blanca, RSP, Antolín, AR, del Cañizo, CG (2023).
Extrauterine Retroperitoneal Leiomyomas: 3 Case Reports and Review of the Literature
UROLOGIA INTERNATIONALIS. Review. 107(8):814-818.
[doi:10.1159/000530213]
de la Blanca, RSP, Medina-Polo, J, González-Padilla, D, Cano-Galán, MM, Arrébola-Pajares, A, Hernández-Arroyo, M, Rodríguez-Antolín, A (2023).
Evaluation of Quality of Life and Self-reported Complications in Patients With Clean Intermittent Catheterization
JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING. Article. 50(5):400-405.
[doi:10.1097/WON.0000000000001002]
Abida, W, Campbell, D, Patnaik, A, Bryce, AH, Shapiro, J, Bambury, RM, Zhang, JS, Burke, JM, Castellano, D, Font, A, Ganju, V, Hardy-Bessard, AC, McDermott, R, Sautois, B, Spaeth, D, Voog, E, Piulats, JM, Pintus, E, Ryan, CJ, Merseburger, AS, Daugaard, G, Heidenreich, A, Fizazi, K, Loehry, A, Despain, D, Simmons, AD, Dowsonz, M, Goy, J, Watkinsz, SP, Chowdhury, S (2023).
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
EUROPEAN UROLOGY. Article. 84(3):321-330.
[doi:10.1016/j.eururo.2023.05.021]
Esteban-Villarrubia, J, Ferreiro, CR, Carril-Ajuria, L, Carretero-González, A, Iacovelli, R, Albiges, L, Castellano, D, de Velasco, G (2023).
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 41(9).
[doi:10.1016/j.urolonc.2023.05.002]
Sutil, RS, Vázquez-Martul, D, de Pablos-Rodríguez, P, Vallejo, EP, Fernández, CA, Lozano, AGF, Tobar, JT, Prieto, GR, Garcia, AC, Backhaus, MR, Abal, VC, Antolín, YAR (2023).
European Association of Urology biochemical recurrence risk groups after radical prostatectomy: external validation and identification of independent risk factors for progression and death
ACTAS UROLOGICAS ESPANOLAS. Article. 47(7):422-429.
[doi:10.1016/j.acuro.2023.01.001]
Font, A, Domenech, M, Ramirez, JL, Marqués, M, Benítez, R, de Porras, VR, Gago, JL, Carrato, C, Sant, F, Lopez, H, Castellano, D, Malats, N, Calle, ML, Real, FX (2023).
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
Frontiers in oncology. Article. 13.
[doi:10.3389/fonc.2023.1155244]
Pal, SK, Albiges, L, Tomczak, P, Suárez, C, Voss, MH, de Velasco, G, Chahoud, J, Mochalova, A, Procopio, G, Mahammedi, H, Zengerling, F, Kim, C, Osawa, T, Angel, M, Gupta, S, Khan, O, Bergthold, G, Liu, B, Kalaitzidou, M, Huseni, M, Scheffold, C, Powles, T, Choueiri, TK (2023).
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
LANCET. Article. 402(10397):185-195.
[doi:10.1016/S0140-6736(23)00922-4]
Hernando, J, Roca-Herrera, M, García-Alvarez, A, Raymond, E, Ruszniewski, P, Kulke, MH, Grande, E, García-Carbonero, R, Castellano, D, Salazar, R, Ibrahim, T, Teule, A, Alonso, V, Fazio, N, Valle, JW, Tafuto, S, Carmona, A, Navarro, V, Capdevila, J (2023).
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
EUROPEAN JOURNAL OF CANCER. Article. 188:39-48.
[doi:10.1016/j.ejca.2023.04.013]
Choueiri, TK, Albiges, L, Tomczak, P, Suárez, C, Voss, MH, de Velasco, G, Chahoud, J, Procopio, G, Mahammedi, H, Zengerling, F, Kim, C, Gupta, S, Bergthold, G, Liu, B, Kalaitzidou, M, Huseni, MA, Scheffold, C, Powles, T, Pal, SK (2023).
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
JOURNAL OF CLINICAL ONCOLOGY. Article. 41(17_SUPPL):4500-4500.
[doi:10.1200/JCO.2023.41.17_suppl.LBA4500]
Carneiro, F, de Velasco, G (2023).
Is immunotherapy safe and effective for older patients with kidney cancer?
JOURNAL OF GERIATRIC ONCOLOGY. Article. 14(5):101527-101527.
[doi:10.1016/j.jgo.2023.101527]
de Vries, EGE, Rüschoff, J, Lolkema, M, Tabernero, J, Gianni, L, Voest, E, de Groot, DJA, Castellano, D, Erb, G, Naab, J, Donica, M, Deurloo, R, van der Heijden, MS, Viale, G (2023).
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
Cancer Medicine. Article. 12(11):12071-12083.
[doi:10.1002/cam4.5893]
Mar, N, Zakharia, Y, Falcon, A, Morales-Barrera, R, Mellado, B, Duran, I, Oh, D, Williamson, SK, Gajate, P, Arkenau, HT, Jones, RJ, Teo, MY, Turan, T, McLaughlin, RT, Peltier, HM, Chong, ELZB, Atluri, H, Dean, JP, Castellano, D (2023).
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
Cancers. Article. 15(11).
[doi:10.3390/cancers15112978]
Gillessen, S, Bossi, A, Davis, ID, de Bono, J, Fizazi, K, James, ND, Mottet, N, Shore, N, Small, E, Smith, M, Sweeney, CJ, Tombal, B, Antonarakis, ES, Aparicio, AM, Armstrong, AJ, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Blanchard, P, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Castellano, D, Castro, E, Cheng, HH, Chi, KN, Chowdhury, S, Clarke, CS, Clarke, N, Daugaard, G, De Santis, M, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ekeke, ON, Evans, CP, Fanti, S, Feng, FY, Fonteyne, V, Fossati, N, Frydenberg, M, George, D, Gleave, M, Gravis, G, Halabi, S, Heinrich, D, Herrmann, K, Higano, C, Hofman, MS, Horvath, LG, Hussain, M, Jereczek-Fossa, BA, Jones, R, Kanesvaran, R, Kellokumpu-Lehtinen, PL, Khauli, RB, Klotz, L, Kramer, G, Leibowitz, R, Logothetis, C, Mahal, B, Maluf, F, Mateo, J, Matheson, D, Mehra, N, Merseburger, A, Morgans, AK, Morris, MJ, Mrabti, H, Mukherji, D, Murphy, DG, Murthy, V, Nguyen, PL, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Pezaro, CJ, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, MA, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, HI, Sharifi, N, Skoneczna, I, Soule, H, Spratt, DE, Srinivas, S, Sternberg, CN, Steuber, T, Suzuki, H, Sydes, MR, Taplin, ME, Tilki, D, Türkeri, L, Turco, F, Uemura, H, Uemura, H, Ürün, Y, Vale, CL, van Oort, I, Vapiwala, N, Walz, J, Yamoah, K, Ye, DW, Yu, EY, Zapatero, A, Zilli, T, Omlin, A (2023).
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
EUROPEAN JOURNAL OF CANCER. Article. 185:178-215.
[doi:10.1016/j.ejca.2023.02.018]
Carles, J, Medina-Lopez, RA, Puente, J, Gómez-Ferrer, A, Nebra, JC, Medina, MIS, Ribal, MJ, Antolín, AR, Alvarez-Ossorio, JL, Novo, JFS, Agut, CM, Srinivasan, S, Ortiz, J, Fizazi, K (2023).
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
FUTURE ONCOLOGY. Article. 19(12):819-828.
[doi:10.2217/fon-2022-1131]
Ossorioa, JLA, Aliagac, MR, Antolind, AR, Urzaize, MU, Callejaf, MA, Ruizg, MD, Quilezh, JB, Millani, IRH, Zalabardoj, DS, Olmo, JMC (2023).
Hormone sensitive protocol for metastatic prostate cancer, an update
ACTAS UROLOGICAS ESPANOLAS. Article. 47(4):244-249.
[doi:10.1016/j.acuro.2022.09.003]
Powles, T, Kockx, M, Rodriguez-Vida, A, Duran, I, Crabb, SJ, van der Heijden, MS, Szabados, B, Pous, AF, Gravis, G, Herranz, UA, Protheroe, A, Ravaud, A, Maillet, D, Mendez, MJ, Suarez, C, Linch, M, Prendergast, A, van Dam, PJ, Stanoeva, D, Daelemans, S, Mariathasan, S, Tea, JS, Mousa, K, Banchereau, R, Castellano, D (2023).
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (vol 25, pg 1706, 2019)
NATURE MEDICINE. Correction.
[doi:10.1038/s41591-023-02312-9]
Fernandez-Perez, MP, Perez-Navarro, E, Alonso-Gordoa, T, Conteduca, V, Font, A, Vazquez-Estevez, S, Gonzalez-del-Alba, A, Wetterskog, D, Antonarakis, ES, Mellado, B, Fernandez-Calvo, O, Mendez-Vidal, MJ, Climent, MA, Duran, I, Gallardo, E, Sanchez, AR, Santander, C, Saez, MI, Puente, J, Tudela, J, Martinez, A, Lopez-Andreo, MJ, Padilla, J, Lozano, R, Hervas, D, Luo, J, de Giorgi, U, Castellano, D, Attard, G, Grande, E, Gonzalez-Billalabeitia, E (2023).
A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate. Article. 83(4):376-384.
[doi:10.1002/pros.24469]
Loehr, A, Hussain, A, Patnaik, A, Bryce, AH, Castellano, D, Font, A, Shapiro, J, Zhang, JS, Sautois, B, Vogelzang, NJ, Chatta, G, Courtney, K, Harzstark, A, Ricci, F, Despain, D, Watkins, S, King, C, Nguyen, M, Simmons, AD, Chowdhury, S, Abida, W (2023).
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
EUROPEAN UROLOGY. Article. 83(3):200-209.
[doi:10.1016/j.eururo.2022.09.010]
Balar, AV, Castellano, DE, Grivas, P, Vaughn, DJ, Powles, T, Vuky, J, Fradet, Y, Lee, JL, Fong, L, Vogelzang, NJ, Climent, MA, Necchi, A, Petrylak, DP, Plimack, ER, Xu, JZ, Imai, K, Moreno, BH, Bellmunt, J, de Wit, R, O'Donnell, PH (2023).
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
ANNALS OF ONCOLOGY. Article. 34(3):289-299.
[doi:10.1016/j.annonc.2022.11.012]
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A (2023).
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
EUROPEAN UROLOGY. Article. 83(3):267-293.
[doi:10.1016/j.eururo.2022.11.002]
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH (2023).
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
NEW ENGLAND JOURNAL OF MEDICINE. Article. 388(8):719-732.
[doi:10.1056/NEJMoa2214676]
Carril-Ajuria, L, Colomba, E, Romero-Ferreiro, C, Cerbone, L, Ratta, R, Barthelemy, P, Vindry, C, Flechon, A, Cherifi, F, Boughalem, E, Linassier, C, Fornarini, G, Rebuzzi, SE, Gross-Goupil, M, Saldana, C, Martin-Soberon, M, de Velasco, G, Manneh, R, Pernaut, C, de Torre, AS, Flippot, R, Escudier, B, Albiges, L (2023).
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status
EUROPEAN JOURNAL OF CANCER. Article. 180:21-29.
[doi:10.1016/j.ejca.2022.11.013]
Fizazi, K, Mella, PG, Castellano, D, Minatta, JN, Kalebasty, AR, Shaffer, D, Limón, JCV, López, HMSA, Armstrong, AJ, Horvath, L, Bastos, DA, Amin, NP, Li, J, Unsal-Kacmaz, K, Retz, M, Saad, F, Petrylak, DP, Pachynski, RK (2023).
Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial
JOURNAL OF UROLOGY. Editorial Material. 209(2):445-446.
Albiges, L, Tannir, NM, Burotto, M, McDermott, D, Plimack, ER, Barthélémy, P, Porta, C, Powles, T, Donskov, F, George, S, Kollmannsberger, CK, Gurney, H, Grimm, MO, Tomita, Y, Castellano, D, Rini, BI, Choueiri, TK, Leung, D, Saggi, SS, Lee, CW, McHenry, MB, Motzer, RJ (2023).
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
JOURNAL OF UROLOGY. Editorial Material. 209(2):442.
Bergerot, C, Rha, SY, Pal, S, Koralewski, P, Stroyakovskiy, D, Alekseev, B, Parnis, F, Castellano, D, Lee, JL, Sunela, K, Ciuleanu, T, Heng, D, Glen, H, Wang, JY, Bennett, L, Pan, J, O'Hara, K, Puente, J (2023).
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
ONCOLOGIST. Article. 28(1):59-71.
[doi:10.1093/oncolo/oyac142]
Santos Pérez de la Blanca R, Medina-Polo J, Peña-Vallejo H, Juste-Álvarez S, Pamplona-Casamayor M, Duarte-Ojeda JM, Miranda Utrera N, García-González L, Arrébola-Pajares A, Rodríguez Antolín A, Tejido-Sánchez Á (2023).
Ureteral Stenosis and Fistula after Kidney Transplantation.
UROLOGIA INTERNATIONALIS. Article. 107(2):1-8.
[doi:10.1159/000523690]
Rosenberg, JE, Park, SH, Kozlov, V, Dao, TV, Castellano, D, Li, JR, Mukherjee, SD, Howells, K, Dry, H, Lanasa, MC, Stewart, R, Bajorin, DF (2023).
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
JOURNAL OF CLINICAL ONCOLOGY. Article. 41(1):43-53.
[doi:10.1200/JCO.22.00205]
Zambrana, F, Barbancho, C, Huelves, M, García de Santiago B, Martín, Y, Muñoz de Lengaria M, de Velasco, G (2023).
Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
JOURNAL OF IMMUNOTHERAPY. Review. 46(1):27-28.
[doi:10.1097/CJI.0000000000000448]
Bamias, A, Merseburger, A, Loriot, Y, James, N, Choy, E, Castellano, D, Lopez-Rios, F, Calabro, F, Kramer, M, de Velasco, G, Zakopoulou, R, Tzannis, K, Sternberg, CN (2023).
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
Journal For Immunotherapy Of Cancer. Article. 11(1).
[doi:10.1136/jitc-2022-005977]
van der Heijden, MS, Powles, T, Petrylak, D, de Wit, R, Necchi, A, Sternberg, CN, Matsubara, N, Nishiyama, H, Castellano, D, Hussain, SA, Bamias, A, Gakis, G, Lee, JL, Tagawa, ST, Vaishampayan, U, Aragon-Ching, JB, Eigl, BJ, Hozak, RR, Rasmussen, ER, Xia, MS, Rhodes, R, Wijayawardana, S, Bell-McGuinn, KM, Aggarwal, A, Drakaki, A (2023).
Re: Predictive Biomarkers for Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial Editorial Comment
JOURNAL OF UROLOGY. Editorial Material. 209(1):291-291.
Santos, M, Lanillos, J, Caleiras, E, Valdivia, C, Roldan-Romero, JM, Lainez, N, Puente, J, Beuselinck, B, Oudard, S, Zucman-Rossi, J, Navarro, P, Robledo, M, Castellano, D, de Velasco, G, Garcia-Donas, J, Rodriguez-Antona, C (2023).
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer
AMERICAN JOURNAL OF CANCER RESEARCH. Article. 13(5):2116-2125.
Gómez Caamaño A, García Vicente AM, Maroto P, Rodríguez Antolín A, Sanz J, Vera González MA, Climent MÁ, On Behalf Of The Spanish Oncology Genitourinary Sogug Multisiciplinary Working G (2021).
Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group.
Current Oncology. Article. 28(6):5084-5100.
[doi:10.3390/curroncol28060428]
Hirsch, L, Chanza, NM, Farah, S, Xie, WL, Flippot, R, Braun, DA, Rathi, N, Thouvenin, J, Collier, KA, Seront, E, de Velasco, G, Dzimitrowicz, H, Beuselinck, B, Xu, WX, Bowman, IA, Lam, ET, Abuqayas, B, Bilen, MA, Varkaris, A, Zakharia, Y, Harrison, MR, Mortazavi, A, Barthelemy, P, Agarwal, N, McKay, RR, Brastianos, PK, Krajewski, KM, Albiges, L, Harshman, LC, Choueiri, TK (2021).
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
JAMA oncology. Article. 7(12):1815-1823.
[doi:10.1001/jamaoncol.2021.4544]
González-Padilla DA, González-Díaz A, Peña-Vallejo H, de la Blanca RSP, Teigell-Tobar J, Hernández-Arroyo M, Abad-López P, Rodriguez-Antolin A, Cabrera-Meiras F (2021).
Long surgical waiting list times are associated with an increased rate of negative ureteroscopies.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL. Article. 15(12):407-411.
[doi:10.5489/cuaj.7199]
Sanchez, AT, Casamayor, MP, Ojeda, JMD, Polo, JM, Utrera, NRM, Gonzalez, LG, Pajares, AA, Antolin, AR (2021).
TREATMENT OF LATE COMPLICATIONS OF RENAL TRANSPLANTATION
ARCHIVOS ESPANOLES DE UROLOGIA. Article. 74(10):1040-1049.
Tejido Sánchez A, Pamplona Casamayor M, Duarte Ojeda JM, Medina Polo J, Miranda Utrera NR, García González L, Arrébola Pajares A, Rodríguez Antolín A (2021).
Tratamiento de las complicaciones tardías del trasplante renal.
ARCHIVOS ESPANOLES DE UROLOGIA. Article. 74(10):1040-1049.
Powles, T, Albiges, L, Bex, A, Grunwald, V, Porta, C, Procopio, G, Schmidinger, M, Suarez, C, de Velasco, G, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021).
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
ANNALS OF ONCOLOGY. Article. 32(12):1511-1519.
[doi:10.1016/j.annonc.2021.09.014]
Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N (2021).
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
JOURNAL OF CLINICAL ONCOLOGY. Article. 39(33):3725-3736.
[doi:10.1200/JCO.21.00939]
Lorente D, Llacer C, Lozano R, de Velasco G, Romero-Laorden N, Rodrigo M, Sánchez-Iglesias Á, di Capua C, Castro E, Ferrer C, Sánchez-Hernández A, Olmos D (2021).
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
EUROPEAN UROLOGY. Article. 80(5):641-649.
[doi:10.1016/j.eururo.2021.07.014]
Sternberg, CN, Castellano, D, de Bono, J, Fizazi, K, Tombal, B, Wulfing, C, Kramer, G, Eymard, JC, Bamias, A, Carles, J, Iacovelli, R, Melichar, B, Sverrisdottir, A, Theodore, C, Feyerabend, S, Helissey, C, Poole, EM, Ozatilgan, A, Geffriaud-Ricouard, C, de Wit, R (2021).
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
EUROPEAN UROLOGY. Article. 80(4):497-506.
[doi:10.1016/j.eururo.2021.06.021]
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Bono J (2021).
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
Esmo Open. Article. 6(5):100241-100241.
[doi:10.1016/j.esmoop.2021.100241]
Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, Castro-Díaz D, Medina-Polo J, Fernández-Gómez JM, Ficarra V, Palou J, Ponce de León Roca J, Angulo JC, Esteban-Fuertes M, Cózar-Olmo JM, Pérez-León N, Molero-García JM, Fernández-Pro Ledesma A, Brenes-Bermúdez FJ, Manasanch J (2021).
Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.
SCIENTIFIC REPORTS. Article. 11(1):19401-19401.
[doi:10.1038/s41598-021-98586-5]
Zambrana F, Carril-Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, de Velasco G (2021).
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
CANCER TREATMENT REVIEWS. Review. 99:102239-102239.
[doi:10.1016/j.ctrv.2021.102239]
Medina-Polo J, Gil-Moradillo J, González-Díaz A, Abad-López P, Santos-Pérez de la Blanca R, Hernández-Arroyo M, Peña-Vallejo H, Téigell-Tobar J, Calzas-Montalvo C, Caro-González P, Miranda-Utrera N, Tejido-Sánchez Á (2021).
Observational study over 8-year period evaluating microbiological characteristics and risk factor for isolation of multidrug-resistant organisms (MDRO) in patients with healthcare-associated infections (HAIs) hospitalized in a urology ward.
Gms Infectious Diseases. Article. 9.
[doi:10.3205/id000073]
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S (2021).
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature. Article. 595(7867):432-437.
[doi:10.1038/s41586-021-03642-9]
Carril-Ajuria L, Colomba E, Cerbone L, Romero-Ferreiro C, Crouzet L, Laguerre B, Thibault C, Vicier C, de Velasco G, Fléchon A, Saldana C, Benusiglio PR, Bressac-de Paillerets B, Guillaud-Bataille M, Gaignard P, Scoazec JY, Richard S, Caron O, Escudier B, Albiges L (2021).
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.
EUROPEAN JOURNAL OF CANCER. Article. 151:106-114.
[doi:10.1016/j.ejca.2021.04.009]
Esteban, E, Exposito, F, Crespo, G, Lambea, J, Pinto, A, Puente, J, Arranz, JA, Redrado, M, Rodriguez-Antona, C, de Andrea, C, Lopez-Brea, M, Redin, E, Rodriguez, A, Serrano, D, Garcia, J, Grande, E, Castellano, D, Calvo, A (2021).
Circulating Levels of the Interferon-gamma-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Cancers. Article. 13(11).
[doi:10.3390/cancers13112849]
Bamias A, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G, Zakopoulou R, Tzannis K, Sternberg CN (2021).
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Esmo Open. Article. 6(3):100152-100152.
[doi:10.1016/j.esmoop.2021.100152]
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S, International Germ Cell Cancer Classification Update Consortium (2021).
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
JOURNAL OF CLINICAL ONCOLOGY. Article. 39(14):1553-1562.
[doi:10.1200/JCO.20.03292]
González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA (2021).
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 23(5):969-979.
[doi:10.1007/s12094-021-02561-5]
Rey-Cárdenas M, Guerrero-Ramos F, Gómez de Liaño Lista A, Carretero-González A, Bote H, Herrera-Juárez M, Carril-Ajuria L, Martín-Soberón M, Sepulveda JM, Billalabeitia EG, Castellano D, de Velasco G (2021).
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future.
CANCER TREATMENT REVIEWS. Review. 93:102142-102142.
[doi:10.1016/j.ctrv.2020.102142]
